Patents Assigned to Linnaeus Therapeutics, Inc.
  • ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS
    Publication number: 20230382896
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Application
    Filed: August 3, 2023
    Publication date: November 30, 2023
    Applicant: Linnaeus Therapeutics, Inc.
    Inventors: Christopher NATALE, Patrick MOONEY, Tina GARYANTES, Wayne LUKE
  • Enantiomerically purified GPER agonist for use in treating disease states and conditions
    Patent number: 11760749
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: September 19, 2023
    Assignee: Linnaeus Therapeutics, Inc.
    Inventors: Christopher Natale, Patrick T. Mooney, Tina Garyantes, Wayne Luke
  • ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS
    Publication number: 20220033385
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Application
    Filed: February 25, 2021
    Publication date: February 3, 2022
    Applicant: Linnaeus Therapeutics, Inc.
    Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE
  • Enantiomerically purified GPER agonist for use in treating disease states and conditions
    Patent number: 10934277
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: March 2, 2021
    Assignee: LINNAEUS THERAPEUTICS, INC.
    Inventors: Christopher Natale, Patrick T. Mooney, Tina Garyantes, Wayne Luke
  • ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS
    Publication number: 20200140417
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Application
    Filed: November 13, 2019
    Publication date: May 7, 2020
    Applicant: Linnaeus Therapeutics, Inc.
    Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE
  • ENANTIOMERICALLY PURIFIED GPER ANGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS
    Publication number: 20200024262
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Application
    Filed: July 22, 2019
    Publication date: January 23, 2020
    Applicant: Linnaeus Therapeutics, Inc.
    Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE